Real-world bleeding risk with ibrutinib

Ibrutinib (Imbruvica)
Photo courtesy of Janssen
The Bruton tyrosine kinase inhibitor ibrutinib has been linked to a 20-fold increased risk of major bleeding in blood cancer patients taking concomitant antiplatelet and anticoagulation therapy in a clinical setting. Caution should be used when weighing the risks and benefits of ibrutinib for patients already taking antiplatelet or anticoagulation therapy, or both, wrote Joseph Mock, MD, of the University of Virginia Health System in Charlottesville, and his colleagues. [Read Article]

Team reports ‘simple’ way for GPs to rule out MM

Blood sample collection
Photo by Juan D. Alfonso
Researchers say they have determined which blood tests can help general practitioners (GPs) rule out a diagnosis of multiple myeloma (MM). The team discovered that plasma viscosity (PV) and erythrocyte sedimentation rate (ESR) were more helpful in ruling out MM than a C-reactive protein (CRP) test. Furthermore, the possibility of MM “is extremely low” in patients with normal hemoglobin (Hb) and normal PV or ESR. [Read Article]

Study links communication, outcomes in cancer

Doctor consults with cancer
patient and her father
Photo by Rhoda Baer
Better communication between cancer patients and healthcare providers may provide tangible benefits, according to research published in JNCCN. Cancer survivors who reported greater satisfaction in communicating with healthcare providers had better general health and mental health, fewer doctor visits, and reduced healthcare spending, when compared to patients who were less satisfied with communication. [Read Article]